Earnings ·
Reports Q3 net sales of $27.2 million and positive adjusted EBITDA of $0.5 million
NAGENiagen Bioscience, Inc.
Niagen Bioscience reported third-quarter 2026 total net sales of $27.2 million, driven by $23.3 million from its Tru Niagen brand. The company posted a net loss of $1.2 million, or $(0.01) per share, but generated positive adjusted EBITDA of $0.5 million and $2.6 million in operating cash flow. Gross margin stood at 62.9%, and the firm ended the quarter with $69.5 million in cash. The company also announced product launches including Niagen Plus At-Home Injections, Niagen NanoCloud skincare, and a new brand campaign featuring Kelly Slater, while expanding distribution to Walmart.com and select retail locations.